Pharvaris Appoints Peng Lu As Chief Medical Officer

Pharvaris B.V., a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2-receptor-mediated indications, has appointed Peng Lu, M.D., Ph.D., to the newly-created position of Chief Medical Officer, a role in which she will oversee global clinical development and regulatory strategies for Pharvaris. Dr. Lu brings 15 years of protein therapeutics and small molecule drug development experience including within genetic rare diseases, and was previously the Vice President, Global Program Lead for rare diseases at Takeda.

“Peng’s strong industry and operational leadership positions Pharvaris for success as we move quickly to develop PHA121 for patients with HAE,” said Berndt Modig, Chief Executive Officer and co-founder of Pharvaris. “Peng has deep experience in HAE drug development from both the clinical and regulatory perspective, which will prove valuable in our clinical development and registration strategies. Her ability to build and manage successful teams fits our vision for the company’s growth in the coming years. Peng will be based in Boston to expand the clinical development and operation teams in the U.S. in addition to our growing team in Europe.”

Dr. Lu added, “Pharvaris has an exciting portfolio and impressive executive team; it will be my privilege to lead the development activities for our lead product candidate, PHA121, to address patients’ strong desire for oral therapies that can treat and prevent HAE attacks. Pharvaris’ portfolio of B2-receptor antagonists provides an exciting platform to address bradykinin-mediated disease broadly. I look forward to growing and evolving Pharvaris with my new colleagues.”

During Dr. Lu’s time at Takeda (via acquisition of Shire), she was instrumental in leading project teams that successfully completed two Phase 3 pivotal HAE studies and achieved global approval of TAKHZYRO® (lanadelumab‐flyo) for the prevention of HAE attacks in the US, EU, and the rest of world. In addition, she has also led the life-cycle management of TAKHZYRO® beyond HAE, looking to broaden indications in other diseases with high unmet medical needs. Prior to Takeda/Shire, Dr. Lu held roles in clinical development, translational research and clinical pharmacology with increasing levels of responsibility at Abbvie and Roche/Genentech, where she was responsible for the design and implementation of early and late development clinical strategies across a broad range of indications including autoimmune, respiratory, and genetic diseases leading to multiple approvals. Dr. Lu received her medical degree from Beijing Medical University and Ph.D. from The University of Texas, Austin, in systems biology.-Bio Space